Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459430 | 0.90 | CHRM2 (0.36) | POLBL3MBTL1NPC1RAB9AGABRA1 | |
| SCHEMBL19395990 | 0.88 | TAAR1 (0.41) | POLBL3MBTL1 | |
| SCHEMBL13541829 | 0.88 | ALDH1A1 (0.42) | POLBL3MBTL1NPC1RAB9AGABRA1 | |
| SCHEMBL19600570 | 0.86 | NPC1 (0.34) | POLBL3MBTL1NPC1RAB9AGABRA1 | |
| SCHEMBL20620458 | 0.86 | ALOX5 (0.35) | POLBL3MBTL1NPC1RAB9AGABRA1 | |
| SCHEMBL104309 | 0.85 | CHRM2 (0.50) | POLBL3MBTL1NPC1RAB9ACYP2C9 | |
| SCHEMBL16213682 | 0.85 | NPC1 (0.36) | POLBL3MBTL1NPC1RAB9AGABRA1 | |
| SCHEMBL19396014 | 0.84 | POLB (0.36) | POLBL3MBTL1NPC1RAB9AALOX5 | |
| SCHEMBL8294313 | 0.84 | ACHE (0.57) | ACHEBCHE | |
| SCHEMBL12304039 | 0.83 | NPC1 (0.35) | POLBL3MBTL1NPC1RAB9AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951083-B2 | Cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879293-B2 | Enzymatic transamination of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9879025-B2 | Transfer hydrogenation of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170360763-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-12-21 | — | — | US | disclosed |
| US-9669011-B2 | Methods of use of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669011-B2 | Methods of use of cyclopamine analogs | INFINITY PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-02-02 | — | — | US | disclosed |
| US-20170022212-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2017-01-26 | — | — | US | disclosed |
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080293755-A1 | Steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer and psoriasis | INFINITY DISCOVERY, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293754-A1 | CYCLOPAMINE ANALOGS | ROYALTY SECURITY, LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080287420-A1 | CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF | INFINITY DISCOVERY, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-20080269272-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7407967-B2 | Cyclopamine analogues and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| US-20070191410-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | ROYALTY SECURITY, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | INFINITY PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7230004-B2 | Cyclopamine analogues and methods of use thereof | INFINITY DISCOVERY, INC. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293755-A1 | Steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer and psoriasis | SHH, SMO, GLI1 | POLB 4332/4885L3MBTL1 4335/4885NPC1 906/4885 |
| US-20170360763-A1 | METHODS OF USE OF CYCLOPAMINE ANALOGS | PDE6C, CRYAB, TUBB3 | POLB 2208/4885L3MBTL1 4789/4885NPC1 252/4885 |
| US-20080287420-A1 | CYCLOPAMINE LACTAM ANALOGS AND METHODS OF USE THEREOF | SHH, GLI1, SMO | POLB 4501/4885L3MBTL1 1813/4885NPC1 805/4885 |
| US-20070191410-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | POLB 3667/4885L3MBTL1 1235/4885NPC1 824/4885 |
| US-20080306127-A9 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | POLB 2857/4885L3MBTL1 963/4885NPC1 2462/4885 |
| US-20170022212-A1 | CYCLOPAMINE ANALOGS | PDE6C, GLI1, SHH | POLB 4597/4885L3MBTL1 4598/4885NPC1 196/4885 |
| US-20170029433-A1 | TRANSFER HYDROGENATION OF CYCLOPAMINE ANALOGS | HVCN1, KCNQ4, KCNQ5 | POLB 2806/4885L3MBTL1 2640/4885NPC1 1065/4885 |
| US-20070161690-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCLAF1 | POLB 2857/4885L3MBTL1 963/4885NPC1 2462/4885 |
| US-20080293754-A1 | CYCLOPAMINE ANALOGS | GLI1, PDE6C, SHH | POLB 4680/4885L3MBTL1 4611/4885NPC1 159/4885 |
| US-20080269272-A1 | CYCLOPAMINE ANALOGUES AND METHODS OF USE THEREOF | SHH, SMO, GLI1 | POLB 3667/4885L3MBTL1 1235/4885NPC1 824/4885 |
| US-20070155705-A1 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | BCL3, BCL2, BCL2L1 | POLB 2072/4885L3MBTL1 877/4885NPC1 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.